Semaglutide
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Semaglutide is listed as metabolic / glp-1 agonist.
- •Type 2 Diabetes
- •Obesity
- •Cardiovascular risk reduction
Regulatory status: FDA-Approved Rx.
Structure & Properties
Compound: Semaglutide; also known as Ozempic, Wegovy, Rybelsus.
Pharmacologic class: Metabolic / GLP-1 Agonist.
Known delivery routes: Subcutaneous, Oral.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
GLP-1 receptor agonist — stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via CNS pathways.
- •Sustained weight reduction (10–15%)
- •HbA1c reduction ~1.5–2.0%
- •Reduced MACE in T2D with CV disease
- •Improved cardiometabolic markers
Human Research
Evidence grade: Clinical RCT (Phase III)
Clinical RCT (Phase III). Phase III SUSTAIN/STEP programs.
Laboratory Research
Phase III SUSTAIN/STEP programs
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
Once weekly, same day each week, any time of day, with or without food. If a dose is missed and the next dose is >48 hrs away, take it; otherwise skip.
Potential interactions and combinations to avoid
- •Tirzepatide, Liraglutide, Exenatide, Retatrutide, Survodutide, CagriSema — do NOT stack GLP-1s
- •Sulfonylureas / insulin without dose reduction — hypoglycemia
- •Personal or family history of medullary thyroid carcinoma / MEN2 — contraindicated
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Nausea, vomiting, diarrhea
- •Pancreatitis (rare)
- •Gallbladder disease
- •Thyroid C-cell tumor warning (rodent data)
Contraindications
- •Personal/family history of medullary thyroid carcinoma
- •MEN-2 syndrome
- •Severe gastroparesis
- •Pregnancy
- •Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome
- •History of pancreatitis or unexplained elevated lipase/amylase
- •Gastroparesis, severe GERD, or chronic gastrointestinal motility disorder
- •History of symptomatic gallstones or biliary disease
- •Active eating disorder, malnutrition, or BMI already in the underweight range
- •Type 1 diabetes as monotherapy for glycemic control
- •Planned surgery/anesthesia without pre-procedure fasting adjustment (aspiration risk)
- •Proliferative diabetic retinopathy with rapid glycemic lowering
- •Severe renal impairment with ongoing dehydration or vomiting
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 0.25–2.4 mg/week (SQ); 3–14 mg/day (oral)
Frequency: Weekly (SQ); Daily (oral)
Cycling: Continuous dosing; titrate every 4 weeks. No formal cycle — chronic therapy with stepwise dose escalation.
Subcutaneous (Ozempic / Wegovy)
Standard for weight loss and T2D. Once weekly, same day.
Pre-filled pen (fixed-dose click) or U-100 insulin syringe for compounded vials. Abdomen, thigh, or upper arm. Prime pen per label. Rotate sites weekly. Refrigerate pen; room temp ≤ 56 days once in use.
Oral (Rybelsus)
T2D only; not approved for weight loss.
3, 7, or 14 mg tablet. First thing on waking, empty stomach, ≤120 mL plain water. Wait 30 min before food, other meds, or more water — bioavailability drops sharply otherwise.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Cagrilintide (as CagriSema) — amylin + GLP-1 synergy
- •5-Amino-1MQ or MOTS-c for metabolic adjuncts (research)
- •Adequate protein intake + resistance training to preserve lean mass
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
Function
Dosing
Recommended Time of Day
Same day each week, any time of day — with or without food.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
- Upper arm / deltoid — Back of the upper arm for SubQ; 2 in below the shoulder bone for IM.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Continuous dosing; titrate every 4 weeks. No formal cycle — chronic therapy with stepwise dose escalation.
Timing & Interactions
- ·Tirzepatide, Liraglutide, Exenatide, Retatrutide, Survodutide, CagriSema — do NOT stack GLP-1s
- ·Sulfonylureas / insulin without dose reduction — hypoglycemia
- ·Personal or family history of medullary thyroid carcinoma / MEN2 — contraindicated
- ·Cagrilintide (as CagriSema) — amylin + GLP-1 synergy
- ·5-Amino-1MQ or MOTS-c for metabolic adjuncts (research)
- ·Adequate protein intake + resistance training to preserve lean mass
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Semaglutide and sync them to Vial Lab.
Benefits
- ·Sustained weight reduction (10–15%)
- ·HbA1c reduction ~1.5–2.0%
- ·Reduced MACE in T2D with CV disease
- ·Improved cardiometabolic markers
Risks
- ·Nausea, vomiting, diarrhea
- ·Pancreatitis (rare)
- ·Gallbladder disease
- ·Thyroid C-cell tumor warning (rodent data)
Contraindications
- ·Personal/family history of medullary thyroid carcinoma
- ·MEN-2 syndrome
- ·Severe gastroparesis
- ·Pregnancy
- ·Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome
- ·History of pancreatitis or unexplained elevated lipase/amylase
- ·Gastroparesis, severe GERD, or chronic gastrointestinal motility disorder
- ·History of symptomatic gallstones or biliary disease
- ·Active eating disorder, malnutrition, or BMI already in the underweight range
- ·Type 1 diabetes as monotherapy for glycemic control
- ·Planned surgery/anesthesia without pre-procedure fasting adjustment (aspiration risk)
- ·Proliferative diabetic retinopathy with rapid glycemic lowering
- ·Severe renal impairment with ongoing dehydration or vomiting
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
FDA-Approved Rx
Veterinary Use (Pets)
Not approved for veterinary use. Anecdotal use in obese dogs / cats is emerging but off-label with meaningful GI-adverse-effect risk.
FDA has issued warnings about compounded GLP-1s in veterinary use.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.